|
CN112175998A
|
|
Chimeric antigen receptor T cell and application thereof
|
|
CN112210539A
|
|
Fourth-generation CAR-T cell and application thereof
|
|
CN112210540A
|
|
CAR-T cell expressing immune regulatory factor and application thereof
|
|
CN112210018A
|
|
Chimeric antigen receptor targeting GPC3 and application thereof
|
|
CN112195157A
|
|
CD19 and CD22 double-target chimeric antigen receptor T cell and application thereof
|
|
CN112226412A
|
|
T cell expressing immune suppression check point receptor molecule and application thereof
|
|
CN112251412A
|
|
BCMA (brain cell activating antigen) targeted chimeric antigen receptor T cell and application thereof
|
|
CN112226462A
|
|
Expression vector for co-expressing secretory IL-7 and selective CCL19 and application thereof
|
|
CN112048481A
|
|
Chimeric antigen receptor NK (natural killer) cell targeting CD19 and application thereof
|
|
CN112048473A
|
|
Method for amplifying NK cells in vitro
|
|
CN112029722A
|
|
NK cell culture medium and application thereof
|
|
CN112029729A
|
|
CD19 and CD22 double-target chimeric antigen receptor NK cell and application thereof
|
|
CN112048480A
|
|
Method for preparing NK (natural killer) sample cells based on electrotransformation
|
|
CN112048482A
|
|
Culture method of NK (natural killer) like cells
|
|
CN112029721A
|
|
Preparation method of activity-enhanced NK cells
|
|
CN112063653A
|
|
Method for preparing NK (natural killer) sample cells based on electrotransfer reprogramming plasmid
|
|
CN111848822A
|
|
CD19 and CD30 double-target chimeric antigen receptor and application thereof
|
|
CN111875711A
|
|
Enhanced immune cell and application thereof
|
|
CN111848819A
|
|
MSLN-targeted chimeric antigen receptor and application thereof
|
|
CN111849896A
|
|
CAR-NK cell culture medium and application thereof
|
